RegeneRx


Commercial Opportunities

RegeneRx has designed each formulation to serve a number of target disease indications within a broad area of interest. Each indication is supported by patents and research data, much of which have been published in peer-reviewed scientific and medical journals. Although RegeneRx cannot pursue all of these indications, partners have an opportunity to optimize indications that are important to their own therapeutic area of focus.

PRODUCT CANDIDATE

TARGET INDICATION

APPROX. US
POPULATION/YEAR*
RGN-137 Epidermolysis Bullosa (EB) 12,000
  Dermal Scarring TBD
RGN-259 Corneal Surgeries 1,300,000
  Sjögren’s Dry Eye 2,800,000
RGN-352 Acute Myocardial Infarction (AMI) 650,000
  Multiple Sclerosis 300,000
  Ischemic Stroke 700,000
  Crohn’s Disease 125,000
  Ulcerative Colitis 160,000
  Epidermolysis Bullosa (EB) 12,000
  Ischemic Renal Disease 1,000,000
RGN-457 Cystic Fibrosis 30,000
  Bronchiectasis 81,000

* DISCLAIMER: Estimates of US Treatable Populations are based on our market research. There is no assurance that these figures are accurate now or will be accurate if and when we commercialize a product that addresses the relevant market.